{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T05:31:07Z","timestamp":1779341467448,"version":"3.51.4"},"reference-count":59,"publisher":"American Association for Cancer Research (AACR)","issue":"12","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The purpose of this study was to assess the feasibility of using the selective estrogen receptor modulator (SERM) acolbifene as a breast cancer prevention agent in premenopausal women. To do so, we assessed change in proliferation in benign breast tissue sampled by random periareolar fine-needle aspiration (RPFNA) as a primary endpoint, along with changes in other risk biomarkers and objective and subjective side effects as secondary endpoints. Twenty-five women with cytologic hyperplasia \u00b1 atypia and \u22652% of breast epithelial cells staining positive for Ki-67, received 20 mg acolbifene daily for 6\u20138 months, and then had benign breast tissue and blood risk biomarkers reassessed. Ki-67 decreased from a median of 4.6% [interquartile range (IQR), 3.1%\u20138.5%] at baseline to 1.4% (IQR, 0.6%\u20133.5%) after acolbifene (P &amp;lt; 0.001; Wilcoxon signed-rank test), despite increases in bioavailable estradiol. There were also significant decreases in expression (RT-qPCR) of estrogen-inducible genes that code for pS2, ER\u03b1, and progesterone receptor (P \u2264 0.026). There was no significant change in serum IGF1, IGFBP3, IGF1:IGFBP3 ratio, or mammographic breast density. Subjective side effects were minimal with no significant increase in hot flashes, muscle cramps, arthralgias, or fatigue. Objective measures showed a clinically insignificant decrease in lumbar spine bone density (DEXA) and an increase in ovarian cysts but no change in endometrial thickness (sonography). In summary, acolbifene was associated with favorable changes in benign breast epithelial cell proliferation and estrogen-inducible gene expression but minimal side effects, suggesting a phase IIB placebo-controlled trial evaluating it further for breast cancer prevention. Cancer Prev Res; 8(12); 1146\u201355. \u00a92015 AACR.<\/jats:p>","DOI":"10.1158\/1940-6207.capr-15-0109","type":"journal-article","created":{"date-parts":[[2015,9,21]],"date-time":"2015-09-21T22:08:31Z","timestamp":1442873311000},"page":"1146-1155","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Clinical Trial of Acolbifene in Premenopausal Women at High Risk for Breast Cancer"],"prefix":"10.1158","volume":"8","author":[{"given":"Carol J.","family":"Fabian","sequence":"first","affiliation":[{"name":"1Department of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce F.","family":"Kimler","sequence":"additional","affiliation":[{"name":"2Department of Radiation Oncology, University of Kansas Medical Center, Kansas City, Kansas."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carola M.","family":"Zalles","sequence":"additional","affiliation":[{"name":"3Mercy Hospital, Miami, Florida."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa A.","family":"Phillips","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trina","family":"Metheny","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian K.","family":"Petroff","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas C.","family":"Havighurst","sequence":"additional","affiliation":[{"name":"4Department of Biostatistics and Medical Informatics, University of Wisconsin Madison, Madison, Wisconsin."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KyungMann","family":"Kim","sequence":"additional","affiliation":[{"name":"4Department of Biostatistics and Medical Informatics, University of Wisconsin Madison, Madison, Wisconsin."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard H.","family":"Bailey","sequence":"additional","affiliation":[{"name":"5University of Wisconsin Carbone Cancer Center, Madison, Wisconsin."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brandy M.","family":"Heckman-Stoddard","sequence":"additional","affiliation":[{"name":"6Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2015,12,3]]},"reference":[{"key":"2022060816281477500_bib1","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1200\/JCO.2013.49.3122","article-title":"Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline","volume":"31","author":"Visvanathan","year":"2013","journal-title":"J Clin Oncol"},{"key":"2022060816281477500_bib2","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1016\/S0140-6736(13)60140-3","article-title":"SERM Chemoprevention of Breast Cancer Overview Group. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data","volume":"381","author":"Cuzick","year":"2013","journal-title":"Lancet"},{"key":"2022060816281477500_bib3","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1200\/JCO.2009.27.8077","article-title":"Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis","volume":"28","author":"Ropka","year":"2010","journal-title":"J Clin Oncol"},{"key":"2022060816281477500_bib4","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1200\/JCO.1999.17.9.2659","article-title":"Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Brest and Bowel Project P-1 Study","volume":"17","author":"Day","year":"1999","journal-title":"J Clin Oncol"},{"key":"2022060816281477500_bib5","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/jnci\/93.1.2","article-title":"Estrogen, selective estrogen receptor modulation, and coronary heart disease. Something or nothing","volume":"93","author":"Jordan","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"2022060816281477500_bib6","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1038\/bjc.2014.109","article-title":"Uptake of tamoxifen in consecutive premenopausal women under surveillance in a high-risk breast cancer clinic","volume":"110","author":"Donnelly","year":"2014","journal-title":"Br J Cancer"},{"key":"2022060816281477500_bib7","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1006\/gyno.1998.5201","article-title":"Ovarian overstimulation and cystic formation in premenopausal tamoxifen exposure: comparison between tamoxifen-treated and nontreated breast cancer patients","volume":"72","author":"Cohen","year":"1999","journal-title":"Gynecol Oncol"},{"key":"2022060816281477500_bib8","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/IGC.0b013e3181a47cbe","article-title":"Effect of tamoxifen on the endometrium and the menstrual cycle of premenopausal breast cancer patients","volume":"19","author":"Buijs","year":"1996","journal-title":"Int J Gynecol Cancer"},{"key":"2022060816281477500_bib9","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1002\/cncr.20981","article-title":"Preferences of women evaluating risks of tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction","volume":"103","author":"Melnikow","year":"2005","journal-title":"Cancer"},{"key":"2022060816281477500_bib10","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0960-0760(99)00065-5","article-title":"EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium","volume":"69","author":"Labrie","year":"1999","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2022060816281477500_bib11","first-page":"331","article-title":"EM-652 (SCH 57068), a pure SERM in the mammary gland and endometrium","volume":"8","author":"Labrie","year":"2001","journal-title":"R\u00e9f\u00e9rences en Gyn\u00e9cologie Obst\u00e9trique"},{"key":"2022060816281477500_bib12","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0960-0760(01)00139-X","article-title":"EM-652 (SCH57068), a pure SERM having complete antiestrogenic activity in the mammary gland and endometrium","volume":"79","author":"Labrie","year":"2001","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2022060816281477500_bib13","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1200\/JCO.2004.05.122","article-title":"Activity and safety of the antiestrogen EM-800, the orally active precursor of acolbifene, in tamoxifen-resistant breast cancer","volume":"22","author":"Labrie","year":"2004","journal-title":"J Clin Oncol"},{"key":"2022060816281477500_bib14","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1023\/A:1026118602273","article-title":"A novel pure SERM achieves complete regression of the majority of human breast cancer tumors in nude mice","volume":"81","author":"Roy","year":"2003","journal-title":"Breast Cancer Res Treat"},{"key":"2022060816281477500_bib15","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/(SICI)1097-0215(19971114)73:4<580::AID-IJC20>3.0.CO;2-C","article-title":"Inhibitory effect of the novel anti-estrogen EM-800 and medroxyprogesterone acetate on estrone-stimulated growth of dimethylbenz(a) anthracene-induced mammary carcinoma in rat","volume":"73","author":"Luo","year":"1997","journal-title":"Int J Cancer"},{"key":"2022060816281477500_bib16","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1093\/jnci\/91.21.1829","article-title":"Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer","volume":"91","author":"Gail","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"2022060816281477500_bib17","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1093\/jnci\/92.15.1217","article-title":"Short-term breast cancer prediction by random periareolar fine-needle aspiration cytology and the Gail risk model","volume":"92","author":"Fabian","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"2022060816281477500_bib18","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/j.1524-4741.1995.tb00260.x","article-title":"Cytologic patterns in random aspirates from women at high and low risk for breast cancer","volume":"1","author":"Zalles","year":"1995","journal-title":"Breast J"},{"key":"2022060816281477500_bib19","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1002\/1097-0142(19901001)66:7<1480::AID-CNCR2820660708>3.0.CO;2-O","article-title":"Prospective evaluation of radiologically directed fine-needle aspiration biopsy of nonpalpable breast lesions","volume":"66","author":"Masood","year":"1990","journal-title":"Cancer"},{"key":"2022060816281477500_bib20","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1158\/1940-6207.CAPR-10-0022","article-title":"Reduction in Ki-67 in benign breast tissue of high risk women with the lignan secoisolariciresinol diglycoside (SDG)","volume":"3","author":"Fabian","year":"2010","journal-title":"Cancer Prev Res"},{"key":"2022060816281477500_bib21","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.repbio.2013.01.179","article-title":"Assessment of RNA in human breast tissue sampled by random periareolar fine needle aspiration and ductal lavage and processed as fixed or frozen specimens","volume":"13","author":"Phillips","year":"2013","journal-title":"Reprod Biol"},{"key":"2022060816281477500_bib22","first-page":"1457","article-title":"Free estradiol and breast cancer risk in postmenopausal women: comparison of measured and calculated values","volume":"12","author":"Endogenous Hormones and Breast Cancer Collaborative Group","year":"2003","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2022060816281477500_bib23","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1210\/jcem.74.4.1548361","article-title":"Representativeness of a single point plasma testosterone level for the long term hormonal milieu in men","volume":"74","author":"Vermeulen","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"key":"2022060816281477500_bib24","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1093\/jnci\/87.9.670","article-title":"Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study","volume":"87","author":"Boyd","year":"1995","journal-title":"J Natl Cancer Inst"},{"key":"2022060816281477500_bib25","first-page":"625","article-title":"The detection of change in mammographic density","volume":"12","author":"Stone","year":"2003","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2022060816281477500_bib26","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0002-9440(10)64879-1","article-title":"Breast cancer risk in usual ductal hyperplasia is defined by estrogen receptor-alpha and Ki-67 expression","volume":"160","author":"Shaaban","year":"2002","journal-title":"Am J Pathol"},{"key":"2022060816281477500_bib27","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s10549-009-0534-7","article-title":"Ki67: a time-varying biomarker of risk of breast cancer in atypical hyperplasia","volume":"121","author":"Santisteban","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"2022060816281477500_bib28","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/jnci\/95.11.779","article-title":"A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers","volume":"95","author":"Decensi","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"2022060816281477500_bib29","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/annonc\/mdq427","article-title":"Prognostic significance of Ki-67 labeling index after short-term presurgical tamoxifen in women with ER-positive breast cancer","volume":"22","author":"DeCensi","year":"2011","journal-title":"Ann Oncol"},{"key":"2022060816281477500_bib30","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/S0959-8049(02)00530-0","article-title":"Effects of low dose tamoxifen on normal breast tissue from premenopausal women","volume":"39","author":"de Lima","year":"2003","journal-title":"Eur J Cancer"},{"key":"2022060816281477500_bib31","doi-asserted-by":"crossref","first-page":"951s","DOI":"10.1158\/1078-0432.951s.11.2","article-title":"Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival","volume":"11","author":"Dowsett","year":"2005","journal-title":"Clin Cancer Res"},{"key":"2022060816281477500_bib32","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s10549-005-4896-1","article-title":"Morphologic and immunophenotypic markers as surrogate endpoints of tamoxifen effect for prevention of breast cancer","volume":"94","author":"Mohsin","year":"2005","journal-title":"Breast Cancer Res Treat"},{"key":"2022060816281477500_bib33","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1158\/1940-6207.CAPR-11-0186","article-title":"Tamoxifen downregulates ets oncogene family members ETV4 and ETV5 in benign breast tissue: implications for durable risk reduction","volume":"4","author":"Euhus","year":"2011","journal-title":"Cancer Prev Res"},{"key":"2022060816281477500_bib34","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10549-005-1483-4","article-title":"GREB 1 is a critical regulator of hormone dependent breast cancer growth","volume":"92","author":"Rae","year":"2005","journal-title":"Breast Cancer Res Treat"},{"key":"2022060816281477500_bib35","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1158\/0008-5472.CAN-03-3326","article-title":"Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells","volume":"64","author":"Frasor","year":"2004","journal-title":"Cancer Res"},{"key":"2022060816281477500_bib36","first-page":"6367","article-title":"PDZK1 and GREB1 are estrogen-regulated genes expressed in hormone-responsive breast cancer","volume":"60","author":"Ghosh","year":"2000","journal-title":"Cancer Res"},{"key":"2022060816281477500_bib37","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1158\/0008-5472.CAN-10-3185","article-title":"Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer","volume":"71","author":"Rhodes","year":"2011","journal-title":"Cancer Res"},{"key":"2022060816281477500_bib38","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/bjc.2012.105","article-title":"CXCR4 activation maintains a stem cell population in tamoxifen-resistant breast cancer cells through AhR signalling","volume":"107","author":"Dubrovska","year":"2012","journal-title":"Br J Cancer"},{"key":"2022060816281477500_bib39","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1023\/B:HIJO.0000032355.66152.b8","article-title":"CXCR4-SDF-1 signalling, locomotion, chemotaxis and adhesion","volume":"35","author":"Kucia","year":"2004","journal-title":"J Mol Histol"},{"key":"2022060816281477500_bib40","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/j.febslet.2007.02.070","article-title":"Epigenetic up-regulation of CXCR4 and CXCL12 expression by 17 beta-estradiol and tamoxifen is associated with formation of DNA methyltransferase 3B4 splice variant in Ishikawa endometrial adenocarcinoma cells","volume":"581","author":"Kubarek","year":"2007","journal-title":"FEBS Lett"},{"key":"2022060816281477500_bib41","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.biopha.2009.04.041","article-title":"Tamoxifen epigenetically modulates CXCL12 expression in MCF-7 breast cancer cells","volume":"64","author":"Pietkiewicz","year":"2010","journal-title":"Biomed Pharmacother"},{"key":"2022060816281477500_bib42","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s10549-012-2104-7","article-title":"Specific transcriptional response of four blockers of estrogen receptors on estradiol-modulated genes in the mouse mammary gland","volume":"134","author":"Calvo","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"2022060816281477500_bib43","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/S0140-6736(97)10384-1","article-title":"Circulating concentrations of insulin-like growth factor-I and risk of breast cancer","volume":"351","author":"Hankinson","year":"1998","journal-title":"Lancet"},{"key":"2022060816281477500_bib44","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1023\/A:1012241505717","article-title":"Effect of low dose tamoxifen on the insulin-like growth factor system in healthy women","volume":"69","author":"Bonanni","year":"2001","journal-title":"Breast Cancer Res Treat"},{"key":"2022060816281477500_bib45","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/jnci\/djh106","article-title":"Tamoxifen and breast density in women at increased risk of breast cancer","volume":"96","author":"Cuzick","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"2022060816281477500_bib46","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s10549-010-1322-0","article-title":"A randomized, placebo-controlled trial (NCIC CTG MAP.2) examining the effects of exemestane on mammographic breast density, bone density, markers of bone metabolism and serum lipid levels in postmenopausal women","volume":"126","author":"Cigler","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"2022060816281477500_bib47","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1056\/NEJMoa1103507","article-title":"Exemestane for breast-cancer prevention in postmenopausal women","volume":"364","author":"Goss","year":"2011","journal-title":"N Engl J Med"},{"key":"2022060816281477500_bib48","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.fertnstert.2007.01.095","article-title":"Gynecologic and hormonal effects of raloxifene in premenopausal women","volume":"88","author":"Premkumar","year":"2007","journal-title":"Fertil Steril"},{"key":"2022060816281477500_bib49","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0002-9378(96)70386-1","article-title":"Ovarian cysts in premenopausal and postmenopausal tamoxifen-treated women with breast cancer","volume":"174","author":"Shushan","year":"1996","journal-title":"Am J Obstet Gynecol"},{"key":"2022060816281477500_bib50","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ejogrb.2004.09.006","article-title":"Ovarian cysts in tamoxifen-treated women with breast cancer","volume":"120","author":"Inal","year":"2005","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"2022060816281477500_bib51","doi-asserted-by":"crossref","first-page":"e66616","DOI":"10.1371\/journal.pone.0066616","article-title":"Tamoxifen and ovarian function","volume":"8","author":"Berliere","year":"2013","journal-title":"PLoS One"},{"key":"2022060816281477500_bib52","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1159\/000185445","article-title":"Sex hormones in postmenopausal women with breast cancer on tamoxifen","volume":"47","author":"Kostoglou-Athanassiou","year":"1997","journal-title":"Horm Res"},{"key":"2022060816281477500_bib53","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1200\/JCO.1996.14.1.78","article-title":"Effect of tamoxifen on bone mineral density measured by dual energy x-ray absorptionmetry in health premenopausal and postmenopausal women","volume":"14","author":"Powles","year":"1996","journal-title":"J Clin Oncol"},{"key":"2022060816281477500_bib54","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1749-6632.2001.tb04012.x","article-title":"Quality of life and tamoxifen in a breast cancer prevention trial: a summary of findings from the NSABP P-1 study. National Surgical Adjuvant Breast and Bowel Project","volume":"949","author":"Day","year":"2001","journal-title":"Ann N Y Acad Sci"},{"key":"2022060816281477500_bib55","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1023\/A:1005999008736","article-title":"Variation in endometrial thickening in women with amenorrhea on tamoxifen","volume":"48","author":"Chang","year":"1998","journal-title":"Breast Cancer Res Treat"},{"key":"2022060816281477500_bib56","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/bjc.2013.324","article-title":"Combined effects of goserelin and tamoxifen on estradiol level, breast density, and endometrial thickness in premenopausal and perimenopausal women with early-stage hormone receptor-positive breast cancer: a randomised controlled clinical trial","volume":"109","author":"Yang","year":"2013","journal-title":"Br J Cancer"},{"key":"2022060816281477500_bib57","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1200\/JCO.2005.11.005","article-title":"Selective estrogen receptor modulators for primary prevention of breast cancer","volume":"23","author":"Fabian","year":"2005","journal-title":"J Clin Oncol"},{"key":"2022060816281477500_bib58","first-page":"1437","article-title":"Selective estrogen receptor modulators: tissue specificity and clinical utility","volume":"9","author":"Martinkovich","year":"2014","journal-title":"Clin Interv Aging"},{"key":"2022060816281477500_bib59","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.steroids.2007.07.009","article-title":"New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer","volume":"72","author":"Jordan","year":"2007","journal-title":"Steroids"}],"container-title":["Cancer Prevention Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerpreventionresearch\/article-pdf\/8\/12\/1146\/1733854\/1146.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerpreventionresearch\/article-pdf\/8\/12\/1146\/1733854\/1146.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T14:58:00Z","timestamp":1748617080000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerpreventionresearch\/article\/8\/12\/1146\/50404\/Clinical-Trial-of-Acolbifene-in-Premenopausal"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,1]]},"references-count":59,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2015,12,3]]},"published-print":{"date-parts":[[2015,12,1]]}},"URL":"https:\/\/doi.org\/10.1158\/1940-6207.capr-15-0109","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/1940-6207.22525611.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1940-6207.22525611","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1940-6207.c.6544821","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1940-6207.c.6544821.v1","asserted-by":"object"}]},"ISSN":["1940-6207","1940-6215"],"issn-type":[{"value":"1940-6207","type":"print"},{"value":"1940-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,1]]}}}